Výsledky vyhledávání - "Soroosh, Soosan"

Akademický článek

Musculoskeletal complaints and its economic impact in an Iranian army hospital.

Autor: Soroosh, Soosan G¹ (AUTHOR) soosansoroosh44@gmail.com, Farbod, Abolfazl² (AUTHOR)

Publikováno v: BMC Musculoskeletal Disorders. 5/18/2024, Vol. 25 Issue 1, p1-6. 6p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Changes in BMD T-score from pre-to post-treatment with biosimilar teriparatide: A single-arm, multi-center study

Autor: Soroush, Mohsen G., Kheirandish, Maryam, Soroosh, Soosan

Publikováno v: In Bone Reports June 2023 18

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Additional file 1 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Autor: Jamshidi, Ahmadreza, Vojdanian, Mahdi, Soroush, Mohsen, Akbarian, Mahmoud, Aghaei, Mehrdad, Hajiabbasi, Asghar, Mirfeizi, Zahra, Khabbazi, Alireza, Alishiri, Gholamhosein, Haghighi, Anousheh, Salimzadeh, Ahmad, Karimzadeh, Hadi, Shirani, Fatemeh, Fard, Mohammad Reza Hatef, Nazarinia, MohammadAli, Soroosh, Soosan, Anjidani, Nassim, Gharibdoost, Farhad

Additional file 1. Comparison of the mean percentage change in BMD in the two treatment groups in the PP and ITT populations.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b3b6f489209ebce044ea041baa9f13

Zobrazit plný text záznamu

Additional file 3 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Additional file 3. Forest plot for comparing Arylia versus Prolia® in terms of mean percent changes in BMD of the lumbar spine (L1-L4), total hip, and femoral neck in 18 months duration of the study. Forest plot demonstrating both t-test analysis an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d2a206fd7809e22e0f07e52ba206463

Zobrazit plný text záznamu

Additional file 2 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Additional file 2. Comparison of the mean percentage changes in BMD in the two treatment groups in the PP and ITT populations with the covariance analysis model.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a63bbcd75c3985bd0ba05dd106185a

Zobrazit plný text záznamu

Additional file 4 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

Additional file 4. Summary of the key safety results.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25139ca9be8982c6ac33c118c1a96991

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání